Equities

Novartis AG

0QLR:LSE

Novartis AG

  • Price (CHF)93.65
  • Today's Change0.565 / 0.61%
  • Shares traded5.61k
  • 1 Year change7.21%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 09:57 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Novartis AG grew revenues 7.57% from 43.38bn to 46.66bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 113.52% net income growth from 6.96bn to 14.85bn.
Gross margin74.61%
Net profit margin19.09%
Operating margin21.86%
Return on assets8.82%
Return on equity19.86%
Return on investment12.43%
More ▼

Cash flow in USDView more

In 2023, Novartis AG increased its cash reserves by 78.17%, or 5.88bn. The company earned 14.46bn from its operations for a Cash Flow Margin of 30.99%. In addition the company generated 5.60bn cash from investing, though they paid out 14.28bn more in financing than they received.
Cash flow per share7.61
Price/Cash flow per share12.92
Book value per share18.37
Tangible book value per share-4.47
More ▼

Balance sheet in USDView more

Novartis AG has a Debt to Total Capital ratio of 40.62%, a lower figure than the previous year's 42.23%.
Current ratio0.903
Quick ratio0.7069
Total debt/total equity0.6855
Total debt/total capital0.4062
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)3.68%
Div growth rate (5 year)6.19%
Payout ratio (TTM)77.34%
EPS growth(5 years)-5.59
EPS (TTM) vs
TTM 1 year ago		58.09
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.